DNMTis function by binding to the active site of DNA methyltransferases, thereby preventing them from adding methyl groups to DNA. This inhibition can lead to the reactivation of hypermethylated and silenced genes. Two primary DNMTis currently used in clinical settings are Azacitidine and Decitabine. These drugs are incorporated into DNA during replication and form covalent bonds with DNMTs, leading to their degradation and a subsequent reduction in methylation levels.
